Abstract:Background: Fibroblast activation protein (FAP) is a cell-surface serine protease that has both dipeptidyl peptidase as well as endopeptidase activities and could cleave substrates at post-proline bond. Previous findings showed that FAP was hard to be detected in normal tissues but significantly up-regulated in remodeling sites like fibrosis, atherosclerosis, arthritis and embryonic tissues. Though increasing evidence has demonstrated the importance of FAP in cancer progression, no multifactorial analysis has been developed to investigate its function in gastrointestinal cancers until now. Methods: By comprehensive use of datasets from The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), scTIME Portal and Human Protein Atlas (HPA), we evaluated the carcinogenesis potential of FAP in gastrointestinal cancers, analyzing the correlation between FAP and poor outcomes, immunology in liver, colon, pancreas as well as stomach cancers. Then liver cancer was selected as example to experimentally validate the pro-tumor and immune regulative role of FAP in gastrointestinal cancers. Results: FAP was abundantly expressed in gastrointestinal cancers, such as LIHC, COAD, PAAD and STAD. Functional analysis indicated that the highly-expressed FAP in these cancers could affect extracellular matrix organization process and interacted with genes like COL1A1, COL1A2, COL3A1 and POSTN. In addition, it was also observed that FAP was positively correlated to M2 macrophages infiltration across these cancers. To verify these findings in vitro , we used LIHC as example and over-expressed FAP in human hepatic stellate LX2 cells, a main cell type that produce FAP in tumor tissues, and then investigate its role on LIHC cells as well as macrophages. Results showed that the medium from FAP-over-expressed LX2 cells could significantly promote the motility of MHCC97H and SK-Hep1 LIHC cells, increase the invasion of THP-1 macrophages and induce them into pro-tumor M2 phenotype. Conclusion: In summary, we employed bioinformatic tools and experiments to perform a comprehensive analysis about FAP. Up-regulation of FAP in gastrointestinal cancers was primarily expressed in fibroblasts and contributes to tumor cells motility, macrophages infiltration and M2 polarization, revealing the multifactorial role of FAP in gastrointestinal cancers progression.

Anti-cancer Effect of Targeting Fibroblast Activation Protein Alpha in Glioblastoma Through Remodeling Macrophage Phenotype and Suppressing Tumor Progression.

Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors

Expression of FAP-1 Correlates with Glioblastoma Proliferation, Migration and Treatment Resistance

P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY

The application of the fibroblast activation protein α-targeted immunotherapy strategy

Effect of Short Hairpin RNA Targeting of Fibroblast Activation Protein on Tumor Growth and Angiogenesis in a 4T1 Murine Breast Cancer Model.

Fibroblast Activation Protein α and Targeted Therapy of Tumor

A multifactorial analysis of FAP to regulate gastrointestinal cancers progression

From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment

Immunotherapy Targeting Fibroblast Activation Protein Inhibits Tumor Growth And Increases Survival In A Murine Colon Cancer Model

Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review

In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment

Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells

Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma

Endogenous bystander killing mechanisms enhance the activity of novel FAP-CAR-T cells against glioblastoma

Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein

Enhanced Anti-Tumor Efficiency of Gemcitabine Prodrug by FAPα-mediated Activation.

Inhibition of FAM83D Displays Antitumor Effects in Glioblastoma Via Down‐regulation of the AKT/Wnt/β‐catenin Pathway

Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.

Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling

FABP4 facilitates epithelial-mesenchymal transition via elevating CD36 expression in glioma cells